Open AccessPeroxisome proliferator‐activated receptor gamma‐ligand‐binding domain mutations associated with familial partial lipodystrophy type 3 disrupt human trophoblast fusion and fibroblast migration
Author(s) -
Shoaito Hussein,
Chauveau Sabine,
Gosseaume Camille,
Bourguet William,
Vigouroux Corinne,
Vatier Camille,
Pienkowski Catherine,
Fournier Thierry,
Degrelle Séverine A.
Publication year - 2020
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.15401
Subject(s) - peroxisome proliferator activated receptor gamma , peroxisome proliferator activated receptor , microbiology and biotechnology , biology , receptor , medicine , chemistry , endocrinology , genetics
Abstract The transcription factor peroxisome proliferator‐activated receptor gamma (PPARG) is essential for placental development, and alterations in its expression and/or activity are associated with human placental pathologies such as pre‐eclampsia or IUGR. However, the molecular regulation of PPARG in cytotrophoblast differentiation and in the underlying mesenchyme remains poorly understood. Our main goal was to study the impact of mutations in the ligand‐binding domain (LBD) of the PPARG gene on cytotrophoblast fusion (PPARG E352Q ) and on fibroblast cell migration (PPARG R262G /PPARG L319X ). Our results showed that, compared to cells with reconstituted PPARG WT , transfection with PPARG E352Q led to significantly lower PPARG activity and lower restoration of trophoblast fusion. Likewise, compared to PPARG WT fibroblasts, PPARG R262G /PPARG L319X fibroblasts demonstrated significantly inhibited cell migration. In conclusion, we report that single missense or nonsense mutations in the LBD of PPARG significantly inhibit cell fusion and migration processes.